As of November 7, 2026, Solid Biosciences Inc. is a publicly traded company (Nasdaq: SLDB). The largest holder reporting an active stake on Schedule 13D is Perceptive Advisors, at 11.2%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Raymond Debbane (9.99%), Fidelity (FMR) (7%), BlackRock (6.5%) (Schedule 13D/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Solid Biosciences Inc.? See the free Snapshot first.
Free to see. No signup.
Is Solid Biosciences Inc. a real, registered company?
- Solid Biosciences Inc. files with the SEC under CIK 1707502 (its SEC filings).
- Its shares are listed under the ticker SLDB on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Charlestown, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Solid Biosciences Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-11-06).
Who are Solid Biosciences Inc.'s owners and officers?
Solid Biosciences Inc.: incorporated in Delaware; business address in Charlestown, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13D/A, 2026-11-06).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2022-12-09)
- : Executive Officer (Form D, 2022-12-09)
- : Executive Officer (Form D, 2022-12-09)
- : Executive Officer (Form D, 2022-12-09)
- : Executive Officer (Form D, 2022-12-09)
- : Executive Officer (Form D, 2022-12-09)
- : Executive Officer (Form D, 2022-12-09)
- : Director (Form D, 2022-12-09)
- : Director (Form D, 2022-12-09)
- : Director (Form D, 2022-12-09)
- : Director (Form D, 2022-12-09)
- : Director (Form D, 2022-12-09)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-06 | Ra Capital Management, L.P. | 10.8% |
| Schedule 13G/A, 2026-08-14 | Vestal Point Capital, LP | 4.8% |
| Schedule 13D/A, 2026-08-14 | Perceptive Advisors LLC | 11.2% |
| Schedule 13G, 2026-08-06 | Fmr LLC | 7% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 6.5% |
| Schedule 13D/A, 2026-06-24 | Ra Capital Management, L.P. | 11.9% |
| Schedule 13G/A, 2026-05-05 | Raymond Debbane | 9.99% |
| Schedule 13G/A, 2026-04-27 | Blackrock, Inc. | 4.7% |
| Schedule 13D/A, 2026-03-17 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13D/A, 2026-03-11 | Perceptive Advisors LLC | 12.9% |
| Schedule 13D/A, 2026-03-10 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13D/A, 2026-03-10 | Bcls Sb Investco, LP | 8.8% |
Questions about who owns Solid Biosciences Inc.
Who owns Solid Biosciences Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Solid Biosciences Inc.: Perceptive Advisors LLC (11.2%, Schedule 13D/A, filed 2026-08-14), Ra Capital Management, L.P. (10.8%, Schedule 13D/A, filed 2026-11-06), Raymond Debbane (9.99%, Schedule 13G/A, filed 2026-05-05), Bcls Sb Investco, LP (8.8%, Schedule 13D/A, filed 2026-03-10) and Fmr LLC (7%, Schedule 13G, filed 2026-08-06); 1 more is listed above.
Who are the largest shareholders of Solid Biosciences Inc.?
By the share each holder's latest filing reports, the largest holders of Solid Biosciences Inc. on this page are Perceptive Advisors LLC (11.2%), Ra Capital Management, L.P. (10.8%) and Raymond Debbane (9.99%).
When did Perceptive Advisors LLC buy into Solid Biosciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13D/A, filed 2026-03-11, reporting 12.9%; its latest, Schedule 13D/A filed 2026-08-14, reports 11.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Solid Biosciences Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Solid Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Solid Biosciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Solid Biosciences Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Perceptive Advisors, a director and 10% owner: 11,833,539 shares (10.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-02-21).
- , a director and 10% owner: 11,833,539 shares (10.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-02-21).
- Perceptive Life Sciences Master Fund Ltd., a director and 10% owner: 11,833,539 shares (10.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-02-21).
- Perceptive Xontogeny Venture Fund, LP, a director and 10% owner: 11,833,539 shares (10.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-02-21).
- , LP, a 10% owner: 5,034,582 shares (4.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-02-21).
Shares outstanding: 111,610,531 as of 2026-10-30, from the company's latest SEC cover page.
How much has Solid Biosciences Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2022-12-09 | $9.20M | $9.20M |
Keep reading
More on Solid Biosciences Inc. and the records around it.
Solid Biosciences Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/solid-biosciences